Operating Expenses
Impairment and restructuring
Eli Lilly Impairment and restructuring increased by 231.7% to $279.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 697.1%, from $35.00M to $279.00M. Over 4 years (FY 2021 to FY 2025), Impairment and restructuring shows an upward trend with a 11.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
High levels indicate significant operational disruption or strategic realignment, often impacting short-term profitability.
Detailed definition
The aggregate expense recognized for asset write-downs and costs associated with restructuring operations, such as facil...
Peer comparison
Frequently used by capital-intensive firms to isolate non-recurring costs from core operating performance.
Metric ID:
msft_impairment_and_restructuringHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $104.50M | $0.00 | $0.00 | $206.50M | $38.10M | $0.00 | $0.00 | $0.00 | $68.00M | $0.00 | $435.00M | $81.60M | $344.40M | $35.00M | $0.00 | $364.90M | $84.10M | $279.00M |
| QoQ Change | — | — | — | -100.0% | — | — | -81.5% | -100.0% | — | — | — | -100.0% | — | -81.2% | +322.1% | -89.8% | -100.0% | — | -77.0% | +231.7% |
| YoY Change | — | — | — | — | — | — | -63.5% | — | — | -100.0% | +78.5% | — | — | — | +406.5% | — | -100.0% | +347.2% | -75.6% | +697.1% |
Range$0.00 – $435.00M
Avg YoY Growth+148.8%
Median YoY Growth+7.5%
Impairment and restructuring at Other Companies
Frequently Asked Questions
- What is Eli Lilly's impairment and restructuring?
- Eli Lilly (LLY) reported impairment and restructuring of $279.00M in Q1 2026.
- How has Eli Lilly's impairment and restructuring changed year-over-year?
- Eli Lilly's impairment and restructuring increased by 697.1% year-over-year, from $35.00M to $279.00M.
- What is the long-term trend for Eli Lilly's impairment and restructuring?
- Over 4 years (2021 to 2025), Eli Lilly's impairment and restructuring has grown at a 11.2% compound annual growth rate (CAGR), from $316.10M to $484.00M.
- What does impairment and restructuring mean?
- Total costs related to restructuring the business and writing down the value of assets.